FindMyKOL
Clinical trialNCT03162562TerminatedPhase 1Interventional

The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer

NCT03162562 is a phase 1 interventional trial sponsored by CanariaBio Inc.. As of 21 Nov 2026, it was terminated. It studies Oregovomab and Poly ICLC in Cancer of Ovary, Neoplasms, Ovarian and 4 more conditions. The registry lists an enrollment of 10 participants at 2 sites in 1 country. The registry lists a start date of 30 May 2017 and a primary completion date of 5 Nov 2020.

SponsorCanariaBio Inc.Enrollment10Cancer of OvaryNeoplasms, OvarianOvarian Cancer RecurrentOvarian Cancer Stage IIIOvarian Cancer Stage IVOvary Cancer
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT03162562
FieldValue
Registry IDNCT03162562
StatusTerminated
PhasePhase 1
Study typeInterventional trial
Lead sponsorCanariaBio Inc.
Enrollment10
Registered sites2
Countries1
ConditionsCancer of Ovary, Neoplasms, Ovarian, Ovarian Cancer Recurrent, Ovarian Cancer Stage III, Ovarian Cancer Stage IV and Ovary Cancer
DrugsOregovomab and Poly ICLC
Start30 May 2017
Primary completion5 Nov 2020
Study completion5 Nov 2020
Last update posted22 Dec 2020

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase Ib study to look at the combination of an antibody immunization vaccine strategy using oregovomab and an investigational stage immune booster (poly ICLC / Hiltonol), both of which have previously been used in combination with other cancer treatments and demonstrated to be active in advanced cancer, but which have not previously been used together. This study will assess the approach as to whether these two drugs can safely add to the response seen with either drug alone, both of which have doses that are based on prior studies. Subjects with stable disease for whom a 12 week break from therapy for their persistent and progressive advanced ovarian cancer is appropriate, who have signed informed consent and for whom baseline clinical information is completed, will receive 4 cycles of oregovomab/Hiltonol immunization every three weeks (weeks 0, 3, 6, and 9). Blood will be obtained for to look for a CA125 specific T cell response at 12 weeks before initiating any additional therapy according to the best clinical judgment of the investigator. At week 16 the subjects will receive a final dose of the combination of oregovomab/Hiltonol and at week 17 will have an additional blood draw for analysis of T-cell response.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Florida, United States1 site
  • Florida Hospital Cancer Institute

    Orlando

Virginia, United States1 site
  • Vcu Massey Cancer Center, Dalton Oncology Clinic

    Richmond

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginia: 1 siteVA1MarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFlorida: 1 siteFL1District of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

OregovomabPoly ICLC
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT03162562

Each answer restates registry values shown on this page.

What is NCT03162562?

NCT03162562 is a phase 1 interventional trial sponsored by CanariaBio Inc.. It studies Oregovomab and Poly ICLC in Cancer of Ovary, Neoplasms, Ovarian and 4 more conditions.

Who leads NCT03162562?

The registry names Christopher Nicodemus, MD FACP (study director, AIT Strategies) as the overall official.

Where does NCT03162562 run?

The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT03162562 study?

The registered drug and biological interventions are Oregovomab and Poly ICLC.

When did NCT03162562 end?

The registry lists a primary completion date of 5 Nov 2020 and a study completion date of 5 Nov 2020. The sponsor last updated the record on 22 Dec 2020.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.